Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2506PO in Amyotrophic Lateral Sclerosis (ALS)
NCT00694941Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of arundic acid in amyotrophic lateral sclerosis (ALS), sponsored by Ono Pharmaceutical. Started Jun 2008; status: completed.
02
Drugs
arundic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00694941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00694941.